Enanta Pharmaceuticals (ENTA) EBT (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly EBT came in at -$13.1 million in Q1 2026, up 45.37% YoY from -$9.0 million in Q1 2025, and down 9.82% on a QoQ basis from -$11.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) EBT (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of EBT data on file, last reported at -$13.1 million in Q1 2026.
- Quarterly EBT rose 45.37% year-over-year to -$13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$61.9 million (up 37.42% YoY) and the FY2025 annual result came in at -$83.5 million, up 29.07% from the prior year.
- EBT fell to -$13.1 million in Q1 2026, from -$11.9 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$11.9 million in Q4 2025 to a low of -$37.6 million in Q1 2023.
- A 5-year average of -$26.4 million and a median of -$29.0 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT decreased 17.26% — and 2025, when it soared 47.53%.
- Tracing ENTA's EBT over 5 years: stood at -$29.0 million in 2022, then slipped by 17.26% to -$34.0 million in 2023, then soared by 33.27% to -$22.7 million in 2024, then soared by 47.53% to -$11.9 million in 2025, then decreased by 9.82% to -$13.1 million in 2026.
- The last three EBT figures came in at -$13.1 million (Q1 2026), -$11.9 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -19.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.47 Mn |
| Mar 31, 2026 | -13.08 Mn |
| Dec 31, 2025 | -11.91 Mn |
| Sep 30, 2025 | -18.67 Mn |
| Jun 30, 2025 | -18.23 Mn |
| Mar 31, 2025 | -23.95 Mn |
| Dec 31, 2024 | -22.71 Mn |
| Sep 30, 2024 | -29.19 Mn |
| Jun 30, 2024 | -23.05 Mn |
| Mar 31, 2024 | -31.52 Mn |
| Dec 31, 2023 | -34.03 Mn |
| Sep 30, 2023 | -29.52 Mn |
| Jun 30, 2023 | -34.84 Mn |
| Mar 31, 2023 | -37.61 Mn |
| Dec 31, 2022 | -29.02 Mn |
| Sep 30, 2022 | -26.33 Mn |
| Jun 30, 2022 | -32.15 Mn |
| Mar 31, 2022 | -33.59 Mn |
| Dec 31, 2021 | -30.15 Mn |
| Sep 30, 2021 | -33.39 Mn |